| (Values in U.S. Thousands) | Mar, 2026 | Dec, 2025 | Sep, 2025 | Jun, 2025 | Mar, 2025 |
| Sales | 40 | 30 | 30 | 40 | 50 |
| Sales Growth | +33.33% | unch | -25.00% | -20.00% | +150.01% |
| Net Income | -5,760 | -2,690 | -2,550 | -2,840 | 6,860 |
| Net Income Growth | -114.13% | -5.49% | +10.21% | -141.40% | +298.84% |
Vivosim Lab Inc (VIVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
VivoSim Labs Inc. is a clinical-stage biotechnology company. It involved in developing drugs which are demonstrated to be effective in three-dimensional human tissues as candidates for drug development. The company focuses on developing novel treatment approaches in inflammatory bowel disease. VivoSim Labs Inc., formerly known as Organovo Holdings Inc., is based in SAN DIEGO, United States.
Fiscal Year End Date: 03/31